Mefloquine

• Description :

  Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K+ channel (KvQT1/minK) antagonist with an IC50 of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research[1][2][3].

• Product Name Alternative :

  Mefloquin

• UNSPSC :

  12352005

• Target :

  Autophagy; Parasite; Potassium Channel; ROS Kinase; SARS-CoV

• Type :

  Reference compound

• Related Pathways :

  Anti-infection; Autophagy; Membrane Transporter/Ion Channel; Protein Tyrosine Kinase/RTK

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer; Infection; Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/mefloquine.html

• Purity :

  99.96

• Solubility :

  DMSO : 200 mg/mL (ultrasonic)

• Smiles :

  O[C@H]([C@]1([H])NCCCC1)C2=CC(C(F)(F)F)=NC3=C(C(F)(F)F)C=CC=C32

• Molecular Formula :

  C17H16F6N2O

• Molecular Weight :

  378.31

• References & Citations :

  [1]Kang J, et al. Interactions of the antimalarial drug mefloquine with the human cardiac potassium channels KvLQT1/minK andHERG. J Pharmacol Exp Ther. 2001 Oct;299 (1) :290-6.|[2]Yan KH, et al. Mefloquine exerts anticancer activity in prostate cancer cells via ROS-mediated modulation of Akt, ERK, JNK and AMPK signaling. Oncol Lett. 2013 May;5 (5) :1541-1545.|[3]Kaho Shionoya, et al. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. Front Microbiol. 2021 Apr 30;12:651403.|[4]Rafael Pacheco-Costa, et al. Reversal of loss of bone mass in old mice treated with mefloquine. Bone. 2018 Sep;114:22-31.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  Plasmodium

• CAS Number :

  [53230-10-7]